Can we change the disease biology of multiple myeloma?

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Despite improvements in disease management, multiple myeloma (MM) remains incurable. Conventional treatment methods are unsatisfactory, leading to a pattern of regression and remission, and ultimately failure. This pattern suggests that one of the possible strategies for improving outcomes is continuous therapy to maintain suppression of the surviving tumor cells. Optimal management of MM requires potent agents and modalities with direct tumoricidal activity, which can also provide continuous suppression of the residual tumor to prevent disease relapse. Immunomodulatory agents exert immunomodulatory and tumoricidal effects, and cause disruption of stromal cell support from the bone marrow microenvironment. Therefore continuous therapy with immumomodulatory agents may be able to provide both tumor reduction and tumor suppression, enabling physicians to consider the possibility of incorporating continuous therapy into the treatment paradigm of patients with MM.

Original languageEnglish (US)
Pages (from-to)S3-S12
JournalLeukemia Research
Issue numberSUPPL.1
StatePublished - Nov 2012


  • Bone marrow microenvironment
  • Cell biology
  • Immunomodulatory drugs
  • Mode of action
  • Multiple myeloma
  • Proteosome inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Can we change the disease biology of multiple myeloma?'. Together they form a unique fingerprint.

Cite this